As well. And thank you for joining us at Sleep Cycle's quarter three 2025 Interim Report Presentation. I'm Erik Jivmark. I'm the CEO of Sleep Cycle.
I'm here together with our CFO and Head of Investor Relations, Elisabeth Hedman.
And in this call, we will walk you through the key highlights from the quarter, our progress on the strategic initiatives, and also provide an update on our financials. Together, we will also address any questions you might have in the Q&A at the end. So we're Sleep Cycle, the world's leading sleep technology company. We have a mission to improve global health by helping people take control of their sleep. Everything we do aims to transform high-quality sleep into an accessible daily habit on a large scale. We're used and loved by millions and are available in more than 180 markets in app stores.
And as part of many wearables today, we're proud to be the world's number one sleep app.
We're helping people to build healthy sleep habits, something that is more needed than ever. But what sets us apart goes far beyond that. At the core of everything we do is our proprietary AI sound model. This technology not only powers the app millions of users rely on each night, but it also creates one of the world's richest health data streams.
With the help of this, we're entering a new phase. We're entering a new phase.
It's not a new strategy. It's a new execution model.
For that strategy, we call it Powered by Sleep Cycle. During quarter three, we presented our Sleep SDK.
Opening up access to this technology.
Partners across wellness, healthcare, wearables, and beyond can now integrate our capabilities directly into their own platforms.
To me, this is an extension of our successful partnership strategy.
We're creating new high-margin revenue opportunities, reaching an audience outside our own app.
Our strategy is clear: continue growing our consumer business while expanding the value of our platform.
On one hand, that means strengthening user acquisition, engagement, and retention. On the other hand, we're building new monetization paths, especially around data technology and medtech with sleep apnea screening.
This dual focus allows us to scale both our reach and our impact.
Throughout the year. We've been very transparent about the fact that the sleep tracking segment has headwinds in the App Store. However, as you can see on the chart with data from Sensor Tower, we're performing relatively better than the entire health and fitness app segment. We're gaining market share in both downloads and revenue. Sleep apps are part of health and fitness. However, when we group together and compare ourselves with our direct competitors, our performance looks even better. We show resilience, and we achieve that by leading with product innovation and a stronger business acumen across the organization.
Speaking of product development, in quarter three, we shipped a liquid glass design alongside iOS 16, making navigation clearer and highlighting premium value.
We prepared the first AI Sleep Coach, planned to be released in quarter four to make the app more proactive, personalized, and habit-forming. Smart alarm refinements continue to improve perceived wake-up quality and are also helping our engagement. We also increased new sales prices by around 10% in key markets because revenue is recognized over 12 months. Reported lag. But the pricing supports our view in the long run. If we look at new sales for September, isolated ARPU was 296 SEK, but adjusted for FX, it was 318.
We have continued to raise prices in October, so currently in the US, which is our largest market, new sales output is close to 500 SEK. Now in October, it's up 25% since July.
This means that we are improving top-line performance over time, and it's also helping us in pricing the product correctly with future partners. And when it comes to partners, things are going very well. They continue to grow, up 55% year over year and 13% quarter over quarter. Partnerships now stand for 11% of total revenue.
To me, partnerships are about reaching new customers without any additional acquisition cost. But it's also about taking control of our own destiny, relying less on storefronts, creating a more diversified and resilient revenue base, and a deeper presence in the wider health ecosystem.
I am expecting the partnerships to continue to grow also in quarter four. But that's not all.
During quarter three, we also took another major leap with our sleep SDK, allowing partners to integrate our world-leading AI sleep analysis into their products. It's contactless, it's real-time, and it's built on years of machine learning commercially. This opens up a new recurring licensing model.
And it also accelerates how we scale our mission beyond our own app.
During quarter three, the focus was to release the SDK for us to move from theoretical discussions with partners into more tangible dialogues. We are at the beginning of our journey, but I'm very excited about the possibilities ahead. But we don't stop with the SDK for other companies to license.
We're also looking to use our own technology in new ways.
So as part of this, we have sleep apnea, which affects over 950 million people worldwide, yet 80% remain undiagnosed. It exposes them to significantly higher risks of heart disease, stroke, and diabetes.
Traditional diagnostics are costly and quite inaccessible.
That's where Sleep Cycle comes in. We're using our proprietary audio-based AI, already trusted by millions nightly, to enable non-invasive smartphone-based apnea screening. No wearables, no cables, no clinic visits.
AI-powered screening uses only the iPhone microphone.
So medical-grade precision with consumer-grade simplicity.
It's such a natural extension of our platform and it's aligned with our mission to improve global health. And importantly, it reflects the shift toward proactive, personalized healthcare.
Our sleep apnea initiative represents one of the most significant growth opportunities for Sleep Cycle. This clinical study we launched in June is now about 20% complete, which marks an important step toward medical certification. As the study progresses, we're also working in parallel on documentation, audits, and commercial optimization. The goal is to be ready for submission to both the FDA and the European notified body toward the end of next year, 2026. Longer term, this initiative opens two strategic revenue paths: new consumer offerings within the app, and future healthtech licensing opportunities with partners in the healthcare ecosystem. So with that, I will hand over to Elisabeth who will walk us through the financial performance for the quarter.